FIELD: chemistry.
SUBSTANCE: present group of inventions refers to medicine, namely to ophthalmology, and involves therapy of eye diseases caused by nonmalignant neovascularisation, and also a medical product and pharmaceutical compositions containing prodrug combretastatin A4.
EFFECT: inventions provide effective therapy ensured with ability of prodrug combretastatin A4 to bind tubulin thereby preventing pathological vessel proliferation.
29 cl, 12 tbl, 5 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND WAYS OF INJECTIONS OF AGENTS BINDING TUBULIN, FOR TREATMENT OF EYE DISEASES | 2004 |
|
RU2359693C2 |
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| METHOD OF TREATING ATROPHIC AGE-RELATED MACULAR DEGENERATION | 2009 |
|
RU2521338C9 |
| METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION | 2009 |
|
RU2668371C2 |
| PREVENTIVE AND THERAPEUTIC AGENT FOR POSTERIOR EYE DISEASES | 2008 |
|
RU2470635C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| PEPTIDES FOR INHIBITING ANGIOGENESIS | 2016 |
|
RU2708375C2 |
| ACTIVE DRUG DELIVERY TO DISTANT EYE REGION BY SUBCONJUNCTIVAL OR PERIOCULAR PRODRUG DELIVERY | 2004 |
|
RU2353393C2 |
| METHOD OF TREATING ELEVATED INTRAOCULAR PRESSURE USING INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEM | 2014 |
|
RU2664686C2 |
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
